NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in EmeryVille, CA, US. The stock last traded at $1.47, down 24.62% on the session, giving a market capitalisation of $39.1M. On trailing twelve-month figures it carries a trailing P/E of 0.10, a net margin of 19628.3%. Its beta of 0.16 implies it has historically moved less than the broad market.
NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris. The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments. The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007. Its corporate headquarters are located in Emeryville, California.
NovaBay Pharmaceuticals, Inc. is most often compared with the following Healthcare names: